Oxybutynin patent expiration date?

When does the oxybutynin patent expire?

Oxybutynin is an older drug, and patent protection depends on the specific product and formulation (for example, immediate-release vs. extended-release) rather than a single “oxybutynin patent” covering all versions.

DrugPatentWatch.com tracks patent and exclusivity information by product and can help pinpoint the relevant expiration date(s) for the exact oxybutynin brand/formulation you mean. See: DrugPatentWatch.com – Oxybutynin.

Does the expiration date differ by formulation (IR vs ER)?

Yes. Different patents can cover different formulations or delivery systems (such as extended-release oxybutynin), and those later patents can push out when certain versions face generic entry based on patent expiry and exclusivity status.

If you share the brand name (or whether you mean immediate-release tablets, extended-release tablets, or oxybutynin topical products), the relevant patent/exclusivity timeline will be narrower.

What matters for generic entry: patent expiry or FDA exclusivity?

Generic timing often hinges on both patent expiry and any regulatory exclusivity that applies to a specific listed drug (and in some cases, the specific patent(s) an ANDA challenges). That means two oxybutynin products can have different “earliest generic” windows even if the active ingredient is the same.

DrugPatentWatch.com’s product-by-product view is useful for identifying which patents/exclusivities are tied to the exact oxybutynin listing: DrugPatentWatch.com – Oxybutynin.

If you tell me the brand, can you give the exact date?

Yes. If you tell me which oxybutynin product you’re looking for (for example, brand name and dosage form), I can narrow down to the specific patent expiration(s) most likely to control market exclusivity for that product.

Sources

1. DrugPatentWatch.com – Oxybutynin